Cancer Center, WeiFang Traditional Chinese Hospital, Weifang, Shandong, China (mainland).
Clinical Institute, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China (mainland).
Med Sci Monit. 2018 Jun 23;24:4305-4316. doi: 10.12659/MSM.908104.
BACKGROUND The method of multiple targets overall control is increasingly used to predict the main active ingredient and potential target group of Chinese traditional medicines and to determine the mechanisms involved in their curative effects. Qingdai is the main traditional Chinese medicine used in the treatment of chronic myelogenous leukemia (CML), but the complex active ingredients and antitumor targets in treatment of CML have not been clearly defined in previous studies. MATERIAL AND METHODS We constructed a protein-protein interaction network diagram of CML with 638 nodes (proteins) and 1830 edges, based on the biological function of chronic myelocytic leukemia by use of Cytoscape, and we determined 19 key gene nodes in the CML molecule by network topological properties analysis in a data bank. Then, we used the Surflex-dock plugin in SYBYL7.3 docking and acquired the protein crystal structures of key genes involved in CML from the chemical composition of the traditional Chinese medicine Qingdai with key proteins in CML networks. RESULTS According to the score and the spatial structure, the pharmacodynamically active ingredients of Qingdai are Isdirubin, Isoindigo, N-phenyl-2-naphthylamine, and Isatin, among which Isdirubin is the most important. We further screened the most effective activity key protein structures of CML to find the best pharmacodynamically active ingredients of Qingdai, according to the binding interactions of the inhibitors at the catalytic site performed in best docking combinations. CONCLUSIONS The results suggest that Isdirubin plays a role in resistance to CML by altering the expressions of PIK3CA, MYC, JAK2, and TP53 target proteins. Network pharmacology and molecular docking technology can be used to search for possible reactive molecules in traditional chinese medicines (TCM) and to elucidate their molecular mechanisms.
多靶标整体控制方法越来越多地用于预测中药的主要活性成分和潜在靶群,并确定其疗效的相关机制。青黛是治疗慢性髓性白血病(CML)的主要中药,但之前的研究并未明确治疗 CML 的复杂活性成分和抗肿瘤靶群。
我们利用 Cytoscape 构建了一个包含 638 个节点(蛋白质)和 1830 个边的 CML 蛋白质-蛋白质相互作用网络图,并通过网络拓扑属性分析在数据库中确定了 CML 分子中的 19 个关键基因节点。然后,我们使用 SYBYL7.3 中的 Surflex-dock 插件,从青黛中药的化学成分中获取与 CML 网络中的关键蛋白相关的 CML 关键基因的蛋白晶体结构。
根据得分和空间结构,青黛的药效活性成分有靛玉红、靛蓝、N-苯基-2-萘胺和靛基质,其中靛玉红最重要。我们进一步筛选了 CML 最有效的活性关键蛋白结构,根据抑制剂在最佳对接组合中在催化部位的结合相互作用,找到青黛药效活性成分的最佳结合。
结果表明,靛玉红通过改变 PIK3CA、MYC、JAK2 和 TP53 靶蛋白的表达,在 CML 耐药中发挥作用。网络药理学和分子对接技术可用于搜索中药中可能的反应性分子,并阐明其分子机制。